Xospata™ (gilteritinib) – New orphan drug approval
November 28, 2018 - The FDA announced the approval of Astellas’ Xospata (gilteritinib), for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.
Top